Product | Company | Disease | Status |
---|---|---|---|
MEDI-501 | MedImmune | Genital Warts HPV | II |
Nabi-HB | Nabi Biopharmaceuticals | Hepatitis B | Market |
Ostavir | Protein Design Labs | Hepatitis B | II |
XTL-002 | XTL Biopharmaceuticals Ltd. | Hepatitis C | I |
Civacir | Nabi Biopharmaceuticals | Hepatitis C | I/II |
1F7 Antibody | Immune Network Ltd. | Hepatitis C, HIV/AIDS | Preclinical |
PRO 140 | Progenics Pharmaceuticals | HIV/AIDS | Preclinical |
hNM01 | AbNovo Inc., Immune Network Ltd. | HIV/AIDS | I |
PRO 367 | Roche Holding Progenics Pharmaceuticals | HIV/AIDS | I/II |
TNX-355 | Tanox, Inc., Biogen, Inc. (Massachusetts) | HIV/AIDS | I |
OraQuick HIV-1 | OraSure Technologies, Inc. | HIV/AIDS | Market |
Cytolin | CytoDyn Amerimmune Pharmaceuticals, Inc. | HIV/AIDS | I/II |
Tipranavir | TIPRANAVIR | HIV/AIDS | III |
HXB | AAI International, AnaaiPharma Company | Herpes Simplex Virus type 2 | Preclinical |
MEDI-491 | MedImmune | Human B19 parvovirus | I |
Synagis™ (Palivizumab) | MedImmune | Respiratory Syncytial Virus | Approved in 1998 |
Numax | MedImmune | Respiratory Syncytial Virus | Preclinical |
INS37217 Intranasal | Inspire Pharmaceuticals | Rhinovirus (common cold) | II |